识别丙型肝炎病毒3型感染患者最佳直接抗病毒方案:系统评价与网络Meta分析
该系统评价与网络Meta分析检索截至2016年3月的PubMed、Embase和Web of Science数据库,纳入27项研究共3415例HCV基因3型感染患者,采用贝叶斯网络Meta分析间接比较含直接抗病毒药物方案。结果显示索磷布韦联合维帕他韦方案在无肝硬化和肝硬化患者中SVR率最高,利巴韦林可提高疗效。
要点
- 无肝硬化患者中,索磷布韦+维帕他韦联合或不联合利巴韦林12周方案SVR率最高(99%和97%)。
- 肝硬化患者中,索磷布韦+维帕他韦24周方案SVR率最高(96%)。
- 利巴韦林在有无肝硬化患者中均增加疗效(OR 2.6-4.5),如可耐受应考虑使用。
核心结论
- 基于贝叶斯网络Meta分析的间接比较发现,含索磷布韦和维帕他韦的方案是HCV基因3型感染患者的最佳选择。
- 分析表明利巴韦林显著提高SVR率,如可耐受应考虑使用。
研究设计与样本
- 系统检索PubMed、Embase和Web of Science数据库截至2016年3月的文献,纳入27项研究共3415例患者。
- 采用贝叶斯网络Meta分析随机效应模型,间接比较有无肝硬化患者的方案,计算每种方案的平均估计SVR及95%可信区间(95% CrI),以及利巴韦林效应的比值比(OR)。
- 重点关注当前推荐方案和监管机构评估中的方案。
主要发现
- 无肝硬化患者中,索磷布韦+维帕他韦联合利巴韦林12周的估计SVR率最高为99%(95% CrI 98%-100%),不联合利巴韦林为97%(95% CrI 95%-99%)。
- 无肝硬化患者中,索磷布韦+达拉他韦+利巴韦林12周的估计SVR率为96%(95% CrI 92%-98%),索磷布韦+聚乙二醇干扰素+利巴韦林12周为95%(95% CrI 91%-98%)。
- 肝硬化患者中,索磷布韦+维帕他韦24周的估计SVR率最高为96%(95% CrI 92%-99%)。
- 肝硬化患者中,索磷布韦+达拉他韦+利巴韦林24周的估计SVR率为94%(95% CrI 87%-98%),索磷布韦+维帕他韦+利巴韦林12周为94%(95% CrI 86%-98%)。
- 利巴韦林在有无肝硬化患者中均增加疗效,OR范围为2.6-4.5。
临床怎么用
- 作者认为,含索磷布韦和维帕他韦的方案是HCV基因3型感染患者的最佳选择。
- 作者建议,利巴韦林如可耐受应考虑使用,因其显著提高SVR率。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Direct-acting antivirals (DAAs) are effective in the treatment of chronic hepatitis C virus (HCV) infection, although results for patients infected with genotype 3 are suboptimal. There are several regimens available, however, direct comparisons have not been made and are unlikely to occur. We aimed to identify the most effective DAA regimen for patients infected with HCV genotype 3 and to assess the role of ribavirin. METHODS: We conducted a systematic search of PubMed, Embase, and Web of Science databases through March 2016. We performed a Bayesian network meta-analysis using a random-effects model to indirectly compare regimens in patients with and without cirrhosis. We calculated mean estimated sustained virologic response (SVR) with 95% credible intervals (95% CrI) per regimen and effect of ribavirin as odds ratio. We focused on current recommended regimens and regimens under evaluation by regulatory authorities. RESULTS: Our search identified 2167 articles; 27 studies (comprising 3415 patients) were included. Among patients without cirrhosis, the greatest rates of SVR were estimated for those receiving sofosbuvir + velpatasvir with ribavirin (99%; 95% CrI, 98%-100%) and without ribavirin (97%; 95% CrI, 95%-99%), sofosbuvir + daclatasvir + ribavirin (96%; 95% CrI, 92%-98%), and sofosbuvir + peginterferon + ribavirin (95%; 95% CrI, 91%-98%), all for 12 weeks. Among patients with cirrhosis, the highest rates of SVR were estimated for those receiving sofosbuvir + velpatasvir for 24 weeks (96%; 95% CrI, 92%-99%), sofosbuvir + daclatasvir + ribavirin for 24 weeks (94%; 95% CrI, 87%-98%), and sofosbuvir + velpatasvir + ribavirin for 12 weeks (94%; 95% CrI, 86%-98%). Ribavirin increases efficacy in patients with and without cirrhosis (odds ratio, 2.6-4.5). CONCLUSIONS: An indirect comparison of DAA-based treatments, using Bayesian network meta-analysis, found regimens containing sofosbuvir and velpatasvir to be the best option for patients with HCV genotype 3 infection. Our analyses indicated that ribavirin significantly increases SVR rates and should be considered if tolerated.
引用
- Berden FA, Aaldering BR, Groenewoud H, et al. Identification of the Best Direct-Acting Antiviral Regimen for Patients With Hepatitis C Virus Genotype 3 Infection: A Systematic Review and Network Meta-analysis. Clin Gastroenterol Hepatol. 2016. PMID: 27840182. doi:10.1016/j.cgh.2016.10.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。